ORIGINAL PAPER
Analysis of the correlation between body weight, body composition, and factor VIII recovery in paediatric patients with severe haemophilia A – a single-centre study
 
More details
Hide details
1
Clinical Department of Paediatric Oncology, Haematology, Clinical Transplantology and Paediatrics of Medical University of Warsaw, Warsaw, Poland
 
2
Clinical Department of Gastroenterology, Child Nutrition and Paediatrics of Medical University of Warsaw, Warsaw, Poland
 
3
Department of Bone Marrow Transplantation, Paediatric Oncology and Haematology, Wrocław Medical University, Wroclaw, Poland
 
 
Submission date: 2023-02-20
 
 
Final revision date: 2023-04-12
 
 
Acceptance date: 2023-04-25
 
 
Publication date: 2023-09-27
 
 
Corresponding author
Katarzyna Koch
Katarzyna Koch, Clinical Department of Paediatric Oncology, Haematology, Clinical Transplantology and Paediatrics of Medical University of Warsaw, Warsaw, Poland
 
 
Pediatr Pol 2023;98(3):203-207
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Haemophilia A (HA) is a rare bleeding disorder. Patients with severe HA have a factor VIII activity of < 1%. The clinical picture of severe HA consists of a propensity for spontaneous haemorrhages to the skin, muscles, joints, and internal organs. To prevent severe complications of bleeds, patients with severe HA receive prophylaxis with deficient clotting factor. Obese people have larger absolute fat free mass (FFM) as well as fat mass than non-obese individuals of the same age, gender and height. Factor VIII (FVIII) concentrates are typically confined to the vascular space. Although the pharmacokinetics (PK) based FVIII dosing is becoming a standard in tailoring the prophylaxis for HA patients, the majority of them are still dosed according to total body weight and this may result in an overdose of FVIII. This study aimed to evaluate the PK of FVIII considering patients’ body weight and body composition using electrical bioimpedance.

Material and methods:
Twenty-one boys with severe HA undergoing plasma-derived factor VIII prophylaxis were enrolled in the study. Patients underwent physical examination, body weight and height measurements, had body composition assessed using electrical bioimpedance, FVIII concentration was measured before and 30 min after FVIII administration, and FVIII recovery was evaluated. Patients completed a questionnaire regarding treatment, physical activity, and bleeding.

Results:
Of the patients who underwent the study, 47.6% had a normal body mass index (BMI), 42.8% were overweight, and 9.5% of patients were underweight. There was a correlation between patients’ BMI and FVIII recovery, FFM and FVIII recovery, and fat mass and FVIII recovery. No relationship was found between FVIII recovery and bleeding rate.

Conclusions:
Determining factor VIII dosage according to FFM requires further study.
REFERENCES (22)
1.
Blanchette V, Srivastava A. Definitions in hemophilia: resolved and unresolved issues. Semin Thromb Hemost 2015; 41: 819-825.
 
2.
Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia. 3rd ed. Haemophilia 2020; 26: 1-158.
 
3.
Żbikowski P, Matysiak M, Łaguna P, Ćwikła J. Artropatia hemofilowa – patogeneza, obraz kliniczny i możliwości diagnostyczne. J Transfus Med 2010; 3: 19-26.
 
4.
Windyga J, Chojnowski K, Klukowska A, et al. Część I: Wytyczne postępowania w hemofilii A i B niepowikłanej inhibitorem czynnika VIII i IX (wydanie zaktualizowane). Acta Haematol Pol 2016; 47: 86-114.
 
5.
Windyga J, Zdziarska J, Ładny J, Zawilska K. Narodowy Program Leczenia Chorych na Hemofilię i Pokrewne Skazy Krwotoczne na lata 2019–2023. Ministerstwo Zdrowia 2018.
 
6.
Klukowska A. Profilaktyka u chorych na hemofilię. Acta Haematol Pol 2009; 40: 493-500.
 
7.
Szajewska H, Horvath-Stolarczyk A. Żywienie i leczenie żywieniowe dzieci i młodzieży. Wydawnictwo Medycyna Praktyczna, Kraków 2017.
 
8.
Björkman S, Oh M, Spotts G, et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012; 119: 612-618.
 
9.
Kułaga Z, Różdżyńska A, Palczewska I, et al. Siatki centylowe wysokości, masy ciała i wskaźnika masy ciała dzieci i młodzieży w Polsce – wyniki badania OLAF.
 
10.
Obesity and overweight [Internet]. Available from: https://www.who.int/news-room/....
 
11.
Abarca-Gómez L, Abdeen ZA, Hamid ZA, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet 2017; 390: 2627-2642.
 
12.
Mazur J, Małkowska-Szkutnik A (red). Zdrowie uczniów w 2018 roku na tle nowego modelu badań HBSC. Instytut Matki i Dziecka, Warszawa 2018.
 
13.
Majumdar S, Morris A, Gordon C, et al. Alarmingly high prevalence of obesity in haemophilia in the state of Mississippi. Haemophilia 2010; 16: 455-459.
 
14.
Wilding J, Zourikian N, Minno MD, et al. Obesity in the global haemophilia population: prevalence, implications and expert opinions for weight management. Obes Rev 2018; 19: 1569-1584.
 
15.
Chang CY, Li TY, Cheng SN, et al. Obesity and overweight in patients with hemophilia: Prevalence by age, clinical correlates, and impact on joint bleeding. J Chin Med Assoc 2019; 82: 289-294.
 
16.
Wong TE, Majumdar S, Adams E, et al. Overweight and obesity in hemophilia: a systematic review of the literature. Am J Prev Med 2011; 41: S369-75.
 
17.
Biere-Rafi S, Baarslag M, Peters M, Kruip M, Kraaijenhagen R, Den Heijer M, et al. Cardiovascular risk assessment in haemophilia patients. Thromb Haemost 2011; 105: 274-278.
 
18.
Young G. New challenges in hemophilia: long-term outcomes and complications. Hematology Am Soc Hematol Educ Program 2012; 2012: 362-368.
 
19.
Feldschuh J, Enson Y. Prediction of the normal blood volume. Relation of blood volume to body habitus. Circulation 1977; 56: 605-612.
 
20.
Hazendonk H, Fijnvandraat K, Lock J, Driessens M, van der Meer F, Meijer K, et al. A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. Haematologica 2016; 101: 1159-1169.
 
21.
van Moort I, Preijers T, Hazendonk HCAM, Schutgens REG, Laros-van Gorkom BAP, Nieuwenhuizen L, et al. Dosing of factor VIII concentrate by ideal body weight is more accurate in overweight and obese haemophilia A patients. Br J Clin Pharmacol 2020; 87: 2602-2613.
 
22.
Delavenne X, Dargaud Y. Pharmacokinetics for haemophilia treaters: Meaning of PK parameters, interpretation pitfalls, and use in the clinic. Thrombosis Research 2020; 192: 52-60.
 
Journals System - logo
Scroll to top